Exciting developments are unfolding in the world of medical technology, particularly from 415 Capital, a venture capital firm based in Munich, Germany.
They’ve just announced the launch of their second fund, named 415 Capital Fund II, with a robust target of €150 million (about $165 million).
Strong Support from Investors
The firm has already secured a significant portion of its target commitments from various limited partners.
Notable backers include the European Investment Fund (EIF), KfW Capital, and Wachstumsfonds Deutschland, which brings together over 20 institutional investors such as insurance companies, foundations, and asset managers.
Additionally, family offices from both Europe and North America are contributing, alongside physician-innovators who are keen to support these medical advancements.
Focus on Life-Saving Technologies
Looking ahead, 415 Capital Fund II aims to invest in transformative, life-saving medical technologies.
The focus will be on innovations targeting cardiovascular and neurovascular diseases—conditions that are the leading causes of death and disability globally and significant contributors to healthcare expenses.
So far, the fund has already invested in two clinical-stage cardiovascular companies, with more investment announcements expected soon.
New Additions to the Investment Committee
Along with the fundraising efforts, 415 Capital has strengthened its team by appointing Azin Parhizgar, PhD, and Ruben Osnabrugge, MD, PhD to its Investment Committee.
This strategic move aims to enhance their expertise and decision-making in selecting promising investment opportunities.
Leadership and Investment Strategy
At the helm of 415 Capital are Frederik Groenewegen, Frank Groenewegen, and David Thompson.
This firm specializes in medical technology investments across Europe, the U.S., and Israel, managing nearly $200 million in assets.
Their investment strategy is particularly focused on clinical-stage innovations in cardiovascular and neurovascular health.
Moreover, they are also looking at neuromodulation, medical robotics, and companies at the intersection of patient monitoring, medical imaging, and artificial intelligence (AI).
What’s Next for 415 Capital?
With the final close of 415 Capital Fund II anticipated by the end of the first quarter of 2025, all eyes will be on how this fund evolves and which groundbreaking technologies it will champion in the ever-evolving landscape of medical innovation.
This article was published on TDPel Media. Thanks for reading!Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn